Virtual press conference: Corona tests for Germany – what is the biotech industry’s view?

Thorough and frequent testing of the population is vital to contain the spread of the coronavirus until a vaccine is available. The biotechnology industry has reacted quickly and, through the development, production and distribution of tests, has made a major contribution to reducing the infection rate in Germany. In a virtual press conference held on 19 May, leading diagnostics providers and members of the biotechnology industry association BIO Deutschland emphasised that sufficient tests were available to test citizens for acute as well as past infections and that testing capacities could also be further increased. The industry experts explained that a clear concept is now required that outlines who should be tested in Germany and how often, so that the industry can continue to produce according to demand. This would also require the establishment of transparent reimbursement models.